Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Assessment of renal function in rheumatoid arthritis: validity of a new prediction method.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Anders HJ, Rihl M, Vielhauer V, Schattenkirchner M.
PMID: 17041340
J Clin Rheumatol. 2002 Jun;8(3):130-3. doi: 10.1097/00124743-200206000-00002.

Medical treatment of patients with rheumatoid arthritis (RA) requires assessment of renal function. Because determination of endogenous creatinine clearance from a 24-hour urine collection is an unreliable and time-consuming procedure, several formulae that predict creatinine clearance from clinical and...

Cite
Anders HJ, Rihl M, Vielhauer V, et al. Assessment of renal function in rheumatoid arthritis: validity of a new prediction method. J Clin Rheumatol. 2002;8(3):130-3doi: 10.1097/00124743-200206000-00002.
Anders, H. J., Rihl, M., Vielhauer, V., & Schattenkirchner, M. (2002). Assessment of renal function in rheumatoid arthritis: validity of a new prediction method. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 8(3), 130-3. https://doi.org/10.1097/00124743-200206000-00002
Anders, Hans-Joachim, et al. "Assessment of renal function in rheumatoid arthritis: validity of a new prediction method." Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases vol. 8,3 (2002): 130-3. doi: https://doi.org/10.1097/00124743-200206000-00002
Anders HJ, Rihl M, Vielhauer V, Schattenkirchner M. Assessment of renal function in rheumatoid arthritis: validity of a new prediction method. J Clin Rheumatol. 2002 Jun;8(3):130-3. doi: 10.1097/00124743-200206000-00002. PMID: 17041340.
Copy Download .nbib Format: NLM
Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug.

Expert opinion on investigational drugs

Schattenkirchner M.
PMID: 15989631
Expert Opin Investig Drugs. 1997 Mar;6(3):321-34. doi: 10.1517/13543784.6.3.321.

Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible isoform of the cyclo-oxygenase (COX)-2 enzyme. This enzyme has a major role in mediating the inflammatory response, while synthesis of prostaglandins required for normal physiological functioning...

Cite
Schattenkirchner M. Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug. Expert Opin Investig Drugs. 1997;6(3):321-34doi: 10.1517/13543784.6.3.321.
Schattenkirchner, M. (1997). Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug. Expert opinion on investigational drugs, 6(3), 321-34. https://doi.org/10.1517/13543784.6.3.321
Schattenkirchner, M. "Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug." Expert opinion on investigational drugs vol. 6,3 (1997): 321-34. doi: https://doi.org/10.1517/13543784.6.3.321
Schattenkirchner M. Meloxicam: a selective COX-2 inhibitor non-steroidal anti-inflammatory drug. Expert Opin Investig Drugs. 1997 Mar;6(3):321-34. doi: 10.1517/13543784.6.3.321. PMID: 15989631.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries